Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models

EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition

(2014) Virginia Rotella et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

(2013) Kyriakos P. Papadopoulos et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical and Marketed Proteasome Inhibitors for Cancer Treatment

(2013) Jiankang Zhang et al.   CURRENT MEDICINAL CHEMISTRY

The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4

(2012) Yan Zang et al.   Autophagy

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

(2012) R. Vij et al.   BLOOD

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells

(2012) Xiaokui Yang et al.   CANCER LETTERS

Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy

(2012) Y. Zang et al.   CLINICAL CANCER RESEARCH

Molecular Mechanisms of Acquired Proteasome Inhibitor Resistance

(2012) Andrew J. Kale et al.   JOURNAL OF MEDICINAL CHEMISTRY

Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo

(2012) G. Dasmahapatra et al.   MOLECULAR CANCER THERAPEUTICS

Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer

(2011) Leonie H.A.M. de Wilt et al.   BIOCHEMICAL PHARMACOLOGY

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer

(2011) Mauricio Escobar et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Molecular mechanisms of cisplatin resistance

(2011) L Galluzzi et al.   ONCOGENE

Acquired Cisplatin Resistance in Human Lung Adenocarcinoma Cells Is Associated with Enhanced Autophagy

(2010) Jing-Hua Ren et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Cancer cell sensitivity to bortezomib is associated with survivin and p53 status but not cancer cell types

(2010) Xiang Linf et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

(2010) Angela M. Davies et al.   Journal of Thoracic Oncology

Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors

(2010) Floriana Morgillo et al.   LUNG CANCER

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

(2009) F. Parlati et al.   BLOOD

Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)

(2009) Tianhong Li et al.   LUNG CANCER

A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer

(2009) Giorgio V. Scagliotti et al.   LUNG CANCER

Targeting the ubiquitin system in cancer therapy

(2009) Daniela Hoeller et al.   NATURE

Bcl-2 Family Proteins Contribute to Apoptotic Resistance in Lung Cancer Multicellular Spheroids

(2008) Tsung-Ming Yang et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

(2008) Deborah J. Kuhn et al.   BLOOD

Advances in and applications of proteasome inhibitors

(2008) Bradley S Moore et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

The Proteasome Inhibitor Bortezomib in Combination with Gemcitabine and Carboplatin in Advanced Non-small Cell Lung Cancer: A California Cancer Consortium Phase I Study

(2008) Angela M. Davies et al.   Journal of Thoracic Oncology

In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies

(2008) Kristina Wiberg et al.   MEDICAL ONCOLOGY